ArticleImmuno-oncology technology2022

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

M W Rohaan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.